ResearcherKanazawa UniversityActive in the last 2 years
Toshinari Minamoto Md
Matched on ORCID iD 0000-0003-4168-996X; OpenAlex author ID A5058032939. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 12
2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper
Papers 7
- Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer. Last author DOI 10.20517/cdr.2023.84↗
- Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer. Last author DOI 10.1111/cas.14668↗
- Nestin phosphorylation at threonines 315 and 1299 correlates with proliferation and metastasis of human pancreatic cancer. Co-author DOI 10.1111/cas.13139↗
- Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. Last author DOI 10.1371/journal.pone.0055289↗
- Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine. Co-author DOI 10.1007/s00535-011-0484-9↗
- Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. Co-author DOI 10.4103/1477-3163.100866↗
- Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: implications for new therapeutic strategies. Last author DOI 10.3390/cancers3010446↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Takeo Shimasaki · 5 shared papers, 2011–2024 · strength 0.37
- Paper Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer. DOI 10.20517/cdr.2023.84↗
- Paper Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. DOI 10.4103/1477-3163.100866↗
- Paper Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: impli… DOI 10.3390/cancers3010446↗
- Tomoharu Miyashita · 2 shared papers, 2020–2024 · strength 0.37
- Masahiro Uehara · 2 shared papers, 2020–2024 · strength 0.37
- Yoshiharu Motoo · 4 shared papers, 2011–2013 · strength 0.13
- Paper Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. DOI 10.4103/1477-3163.100866↗
- Paper Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: impli… DOI 10.3390/cancers3010446↗
- Paper Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. DOI 10.1371/journal.pone.0055289↗
- Ayako Kitano · 3 shared papers, 2012–2013 · strength 0.10
- Paper Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. DOI 10.4103/1477-3163.100866↗
- Paper Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. DOI 10.1371/journal.pone.0055289↗
- Paper Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine. DOI 10.1007/s00535-011-0484-9↗
- Hisashi Yoshimura · 1 shared paper, 2017 · strength 0.08
- Yoko Matsuda · 1 shared paper, 2017 · strength 0.08
- Tomio Arai · 1 shared paper, 2017 · strength 0.08
- Toshiyuki Ishiwata · 1 shared paper, 2017 · strength 0.08
- Yoshimichi Sai · 1 shared paper, 2013 · strength 0.03
- Naohisa Tomosugi · 1 shared paper, 2012 · strength 0.03
- Takanobu Takata · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.